DDIT3 and diffuse large B-cell lymphoma: Of note, in 2022, after the end of the present study recruitment, the POLARIX study showed a benefice of the R-CHOP and polatuzumab vedotin combination as compared to R-CHOP, with a benefice mainly observed within patients with an ABC DLBCL.